Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models

19Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Cancer-associated cachexia is characterized, among other symptoms, by a dramatic loss of both muscle and fat. In addition, the cachectic syndrome is often associated with anemia. The object of the present investigation was to assess the effects of erythropoietin (EPO) treatment on experimental cancer cachexia models. The results clearly show that, in addition to the improvement of the hematocrit, EPO treatment promoted a partial preservation of adipose tissue while exerting negligible effects on muscle loss. Administration of EPO to tumor-bearing animals resulted in a significant increase of lipoprotein lipase (LPL) activity in adipose tissue, suggesting that the treatment favored triacylglycerol (TAG) accumulation in the adipose tissue. In vitro experiments using both adipose tissue slices and 3T3-L1 adipocytes suggests that EPO is able to increase the lipogenic rate through the activation of its specific receptor (EPOR). This metabolic pathway, in addition to TAG uptake by LPL, may contribute to the beneficial effects of EPO on fat preservation in cancer cachexia. Copyright © 2013 by the American Society for Biochemistry and Molecular Biology, Inc.

Cite

CITATION STYLE

APA

Penna, F., Busquets, S., Toledo, M., Pin, F., Massa, D., López-Soriano, F. J., … Argilés, J. M. (2013). Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models. Journal of Lipid Research, 54(11), 3045–3051. https://doi.org/10.1194/jlr.M038406

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free